This phase II trial is trying to understand how safe and effective a targeted therapy (nemtabrutinib) is in people with blood cancers.
This trial is treating patients with chronic lymphocytic leukaemia/ small lymphocytic lymphoma, Richter's transformation, marginal zone lymphoma, mantle cell lymphoma, follicular lymphoma, and Waldenström's macroglobulinemia .
This is a systemic therapy trial.
You may be able to join this trial if:
- You are able to swallow medication by mouth.
You may be excluded from this trial if:
- You have a certain disease or psychological condition.
- You have had certain treatments, surgical procedures or drugs.
- You have previously been treated (or are currently being treated) on a clinical trial.
Clinical trials have complex eligibility criteria - talk to your doctor about your interest in this trial.
Clinical Summary Read More
Use the hyperlinks, where available to access additional clinical trial information.
A Phase 2 Study to Evaluate the Efficacy and Safety of MK-1026 in Participants With Hematologic Malignancies
This is a non-randomised trial for people with haematological malignancies of chronic lymphocytic leukaemia (CLL)/ small lymphocytic lymphoma (SLL), Richter's transformation, marginal zone lymphoma (MZL), mantle cell lymphoma (MCL), follicular lymphoma (FL), and Waldenström's macroglobulinemia (WM). The trial has two parts: Dose Escalation and Confirmation (Part 1) and Cohort Expansion (Part 2). Following determination of a recommended phase 2 dose (RP2D) in Part 1, the study plans to proceed with Part 2 using 8 disease-specific expansion cohorts (Cohorts A to H). Participants will receive nemtabrutinib orally once daily until progressive disease or discontinuation.
Recruiting Hospitals Read More